OncoHost announced that it has been named a Gold Winner in the 2025 Merit Awards for Business in the Research and Development category.
Presented annually by the Merit Awards, this program celebrates the world’s most innovative companies and individuals driving measurable progress across industries. OncoHost was selected for its groundbreaking R&D work powering the PROphet platform - an AI-driven proteomics solution that analyzes the patient’s plasma proteome using bioinformatics and machine learning to deliver both predictive power and biological explainability.
OncoHost’s R&D framework brings together machine learning, proteomics, systems biology, and translational medicine. Its multidisciplinary team, including theoretical physicists, molecular biologists, algorithm developers, and clinicians—works collaboratively to investigate mechanisms of treatment resistance and support the expansion of new clinical indications.
The company’s flagship product, PROphetNSCLC, is the first AI-powered liquid biopsy proteomics test developed to guide first-line immunotherapy decisions in metastatic non-small cell lung cancer (NSCLC). Following its success, PROphetRCC (renal cell carcinoma) and PROphetMELANOMA are currently in advanced clinical development and have entered the launch phase.
Beyond immunotherapy response prediction, OncoHost is broadening the platform’s clinical utility with the development of PROphetirAE, a tool designed to identify patients at risk of severe immune-related adverse events before treatment begins.
